The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in Science Advances detailing the company's CRISPR-based Cellgorithm technology, ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting market ...

The Science Advances publication details Cellgorithm™, a CRISPR-based technology that gives researchers greater control over gene activity and sets the stage for future applications in stem cell ...

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...